Literature DB >> 6981168

Activity of trimethoprim-sulfamethoxazole against Chlamydia trachomatis in vitro.

M R Hammerschlag.   

Abstract

With use of a technique for cell culture, the minimal inhibitory concentration (MICs) of trimethoprim (TMP) and sulfamethoxazole (SMZ), alone and in combination at ratios of 1:1, 1:5, and 1:20, were determined against five strains of Chlamydia trachomatis. The drugs were added to idoxuridine-treated McCoy cells after inoculation of the cells with the pathogen. Cultures were examined after incubation for 48 hr; the MIC was defined as the highest concentration of drugs at which no inclusions were seen. Definite end points were observed only with inocula of less than or equal to 10(3) inclusion-forming units (IFU)/ml. With larger inocula, inclusions were present for all dilutions tested. The MICs for TMP alone were greater than or equal to 64 micrograms/ml for all strains. The MICs for SMZ alone ranged from 2 to 128 micrograms/ml. There appeared to be no better than an additive effect for all combinations of TMP and SMZ tested, although the effect of 1:20 was greater than that at 1:1 or 1:5. With increasing concentrations of both drugs, the inclusions became progressively fewer, smaller, and pyknotic. Even though definite end points could not be determined, there was a significant reduction in the number of IFU/ml at relatively low concentrations of both TMP and SMZ. The results of this study suggest that the activity of TMP-SMZ against C. trachomatis is primarily that of SMZ alone.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6981168     DOI: 10.1093/clinids/4.2.500

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  15 in total

1.  Ultrastructural study of Chlamydia pneumoniae in a continuous-infection model.

Authors:  A Kutlin; C Flegg; D Stenzel; T Reznik; P M Roblin; S Mathews; P Timms; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

2.  Trimethoprim- sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions.

Authors:  M A Kielhofner
Journal:  Tex Heart Inst J       Date:  1990

3.  N-acylated derivatives of sulfamethoxazole and sulfafurazole inhibit intracellular growth of Chlamydia trachomatis.

Authors:  Sania Marwaha; Hanna Uvell; Olli Salin; Anders E G Lindgren; Jim Silver; Mikael Elofsson; Asa Gylfe
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

4.  In vitro activity of sulphamethoxazole/trimethoprim and sulfadoxine/pyrimethamine against Chlamydia trachomatis SA2f in McCoy cell culture.

Authors:  G Mumtaz; G L Ridgway; D Felmingham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

Review 5.  Trimethoprim resistance.

Authors:  P Huovinen
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

6.  A comparison of oxytetracycline and trimethoprim in the treatment of Chlamydia trachomatis urethritis.

Authors:  P B Nielsen; J D Christensen; G Frentz
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

7.  Rapid determination of MICs of 15 antichlamydial agents by using an enzyme immunoassay (Chlamydiazyme).

Authors:  A Bianchi; C Scieux; C M Salmeron; I Casin; Y Perol
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

8.  In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.

Authors:  S A Kohlhoff; P M Roblin; T Reznik; S Hawser; K Islam; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Treatment of acute gonococcal urethritis in men with simultaneous infection with Chlamydia trachomatis.

Authors:  P A Csángó; A Salveson; T Gundersen; G Jagars; O Bjerk
Journal:  Br J Vener Dis       Date:  1984-04

Review 10.  Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis.

Authors:  W L Beatty; R P Morrison; G I Byrne
Journal:  Microbiol Rev       Date:  1994-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.